Dova Pharmaceuticals Inc (DOVA)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Dova Pharmaceuticals Inc (DOVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013421
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Dova Pharmaceuticals Inc (Dova) is a clinical-stage pharmaceutical company that develops therapies for the treatment of orphan diseases. The company’s lead candidate, Avatrombopag (AVA), a novel, oral thrombopoietin receptor agonist, is under development for the treatment of thrombocytopenia in patients suffering from chronic liver disease. AVA stimulates platelet production and limits platelet transfusion-associated risks including infections, immune reactions and refractories. As AVA is in a tablet form, the patient can take it at home without the need to visit the infusion center. The compound has recently completed two pivotal Phase III clinical trials. Dova is headquartered in Charlottesville, Virginia, the US.

Dova Pharmaceuticals Inc (DOVA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Dova Pharma Raises USD10 Million in Venture Financing 10
Equity Offering 11
Dova Pharma Raises USD75 Million in IPO 11
Dova Pharma Raises USD0.2 Million in Private Placement of Units 13
Acquisition 14
Perceptive Advisor Acquires 6.8% Stake in Dova Pharma 14
Dova Pharma Acquires AkaRx from Eisai 15
Dova Pharmaceuticals Inc – Key Competitors 16
Dova Pharmaceuticals Inc – Key Employees 17
Dova Pharmaceuticals Inc – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Financial Announcements 19
Nov 09, 2017: Dova Pharmaceuticals Reports Third Quarter 2017 Operating and Financial Results 19
Aug 10, 2017: Dova Pharmaceuticals Reports Second Quarter 2017 Operating and Financial Results 20
Corporate Communications 21
Jan 06, 2017: Dova Pharmaceuticals Announces Hiring of CEO and Presentation at the 35th Annual J.P. Morgan Healthcare Conference 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Dova Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Dova Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Dova Pharma Raises USD10 Million in Venture Financing 10
Dova Pharma Raises USD75 Million in IPO 11
Dova Pharma Raises USD0.2 Million in Private Placement of Units 13
Perceptive Advisor Acquires 6.8% Stake in Dova Pharma 14
Dova Pharma Acquires AkaRx from Eisai 15
Dova Pharmaceuticals Inc, Key Competitors 16
Dova Pharmaceuticals Inc, Key Employees 17
Dova Pharmaceuticals Inc, Subsidiaries 18

★海外企業調査レポート[Dova Pharmaceuticals Inc (DOVA)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SK Kaken Co Ltd (4628):企業の財務・戦略的SWOT分析
    SK Kaken Co Ltd (4628) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Reynolds American Inc.:企業の戦略的SWOT分析
    Reynolds American Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Greencore Group Plc:企業の戦略・SWOT・財務情報
    Greencore Group Plc - Strategy, SWOT and Corporate Finance Report Summary Greencore Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • UTC Engenharia SA:企業の戦略的SWOT分析
    UTC Engenharia SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Purdue Pharma Canada:製薬・医療:M&Aディール及び事業提携情報
    Summary Purdue Pharma Canada, a subsidiary of Purdue Pharma LP is a research-based pharmaceutical company that offers services such as development, manufacturing and commercialization of medicines for patients and healthcare professionals. The company portfolio of products includes antiseptics, laxa …
  • Mitsui Fudosan Co Ltd (8801):企業の財務・戦略的SWOT分析
    Mitsui Fudosan Co Ltd (8801) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Litani River Authority:企業の戦略的SWOT分析
    Litani River Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • PT. Millennium Pharmacon International TBK (SDPC):企業の財務・戦略的SWOT分析
    PT. Millennium Pharmacon International TBK (SDPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Repligen Corp (RGEN):企業の財務・戦略的SWOT分析
    Summary Repligen Corp (Repligen) is a bioprocessing life science company that develops and commercializes consumable products for manufacturing biological drugs. The company's products include Protein A affinity resins, Protein A ligands, ELISA kits, alternating tangential flow system, OPUS pre pack …
  • AB-Biotics SA (ABB):製薬・医療:M&Aディール及び事業提携情報
    Summary AB-Biotics SA (AB-Biotics) is a provider of probiotics, pipeline products, specialty dietary supplements, and other functional ingredients. The company’s products comprise iron-containing ingredients, lactobacillus plantarum, probiotic products, gastrointestinal treatment products, proprieta …
  • Proximus plc (PROX):企業の財務・戦略的SWOT分析
    Proximus plc (PROX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Novanta Inc (NOVT):企業の財務・戦略的SWOT分析
    Novanta Inc (NOVT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • The Swatch Group Ltd:企業の戦略・SWOT・財務情報
    The Swatch Group Ltd - Strategy, SWOT and Corporate Finance Report Summary The Swatch Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Can-Fite BioPharma Ltd (CANF):企業の財務・戦略的SWOT分析
    Summary Can-Fite BioPharma Ltd (Can-Fite) is a clinical stage drug development Company that strives to develop small molecule drugs for the treatment of cancer and inflammatory diseases. The company’s pipeline products which are in phase II and III clinical development stage includes CF101, for rheu …
  • Fidia farmaceutici SpA-製薬・医療分野:企業M&A・提携分析
    Summary Fidia farmaceutici SpA (Fidia), a subsidiary of P&R S.p.A., is a healthcare products provider that specializes in research, development and manufacturing of hyaluronic acid-based products. The company develops and commercializes products for specific therapeutic areas which includes joint he …
  • East-Central Iowa Rural Electric Cooperative:企業の戦略的SWOT分析
    East-Central Iowa Rural Electric Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Dunelm Group plc (DNLM):企業の財務・戦略的SWOT分析
    Dunelm Group plc (DNLM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Alliqua BioMedical Inc (ALQA)-製薬・医療分野:企業M&A・提携分析
    Summary Alliqua BioMedical Inc (Alliqua BioMedical), formerly HepaLife Technologies Inc is a regenerative technology company that builds a suite of regenerative solutions for wound and tissue repair. The company’s product categories include ultrasound healing therapy, human biologics, antimicrobial …
  • Oci Nv:企業の戦略・SWOT・財務分析
    Oci Nv - Strategy, SWOT and Corporate Finance Report Summary Oci Nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • National Mobile Telecommunications Company K.S.C.P.:企業の戦略・SWOT・財務分析
    National Mobile Telecommunications Company K.S.C.P. - Strategy, SWOT and Corporate Finance Report Summary National Mobile Telecommunications Company K.S.C.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's stru …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆